Related Experiment Videos
Mycoplasma pneumoniae vaccine: antigenicity of buffered antigens in volunteers
Abstract:
The antigenicity of experimental Mycoplasma pneumoniae vaccines prepared from antigen grown in a medium buffered with N-2-hydroxyethylpiperazine-N'-2'-ethanesulfonic acid was tested in young, adult males. Formalin-inactivated antigens from a high-passage strain and a low-passage strain at various dilutions (12 to 123 mug of N/ml) were injected intramuscularly in 1-ml doses. Antibody responses were tested by the metabolic inhibition (MI) technique. Sixty-five to 86% of the volunteers in all vaccine groups responded with fourfold or greater MI antibody rises, but only nine (39%) of 23 antibody-free subjects converted compared to 53 (88%) of 60 of those with pre-existing antibody. A booster vaccination did not increase the number of converters or enhance the geometric mean titers. The antigen concentrations of vaccines with 24 or more mug of N/ml appeared to be above the threshold needed for maximal antibody responses in the dose range tested. MI antibody rises could not be detected in sputa and nasal washings obtained from a small group of vaccinees. The results of this study suggest that the new vaccines offer little or no improvement in antigenicity in man over earlier inactivated vaccines.
Insights
New Mycoplasma pneumoniae vaccines showed similar antigenicity to older versions. Antibody responses were observed, but conversion rates in antibody-naive individuals were low, suggesting limited improvement for Mycoplasma pneumoniae vaccine development.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Mycoplasma pneumoniae is a significant cause of respiratory illness.
- Development of effective vaccines against M. pneumoniae is crucial for public health.
- Previous inactivated vaccines have shown variable efficacy.
Purpose of the Study:
- To evaluate the antigenicity of novel experimental Mycoplasma pneumoniae vaccines in human subjects.
- To compare the antibody response elicited by different vaccine preparations.
- To determine if new vaccine formulations offer improved antigenicity over existing ones.
Main Methods:
- Experimental vaccines were prepared using formalin-inactivated M. pneumoniae antigens.
- Antigens were grown in a medium buffered with N-2-hydroxyethylpiperazine-N'-2'-ethanesulfonic acid.
- Volunteers received intramuscular injections of vaccine at various antigen dilutions; antibody responses were measured using the metabolic inhibition (MI) technique.
Main Results:
- 65-86% of volunteers showed significant antibody rises (≥4-fold MI titer increase).
- Subjects with pre-existing antibodies had higher conversion rates (88%) compared to antibody-naive subjects (39%).
- Booster vaccinations did not improve conversion rates or geometric mean titers; antigen concentrations ≥24 µg N/ml appeared sufficient for maximal response.
Conclusions:
- The tested experimental Mycoplasma pneumoniae vaccines demonstrate limited improvement in antigenicity compared to earlier inactivated vaccines.
- The immune response varied significantly between individuals with and without prior antibody exposure.
- Further research is needed to enhance the immunogenicity of M. pneumoniae vaccines, particularly for antibody-naive populations.